{"name":"Ze-yang Ding, MD","slug":"ze-yang-ding-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Bevacizumab Biosimilar IBI305 plus sintilimab","genericName":"Bevacizumab Biosimilar IBI305 plus sintilimab","slug":"bevacizumab-biosimilar-ibi305-plus-sintilimab","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Bevacizumab plus Atezolizumab","genericName":"Bevacizumab plus Atezolizumab","slug":"bevacizumab-plus-atezolizumab","indication":"Non-small cell lung cancer, metastatic or recurrent","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"apatinib plus camrelizumab","genericName":"apatinib plus camrelizumab","slug":"apatinib-plus-camrelizumab","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Bevacizumab Biosimilar IBI305 plus sintilimab","genericName":"Bevacizumab Biosimilar IBI305 plus sintilimab","slug":"bevacizumab-biosimilar-ibi305-plus-sintilimab","phase":"phase_2","mechanism":"Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.","indications":["Non-small cell lung cancer","Colorectal cancer"],"catalyst":""},{"name":"Bevacizumab plus Atezolizumab","genericName":"Bevacizumab plus Atezolizumab","slug":"bevacizumab-plus-atezolizumab","phase":"phase_2","mechanism":"Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune response.","indications":["Non-small cell lung cancer, metastatic or recurrent","Renal cell carcinoma, metastatic","Urothelial carcinoma, locally advanced or metastatic"],"catalyst":""},{"name":"apatinib plus camrelizumab","genericName":"apatinib plus camrelizumab","slug":"apatinib-plus-camrelizumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}